Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,686 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07203404RecruitingEarly Phase 1
A study of a universal CAR-T cell therapy for autoimmune diseases
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07029737RecruitingPhase 2
Studying acalabrutinib with R-CHOP for untreated mantle cell lymphoma
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
A CoruñaAges 18–130 - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT07227350RecruitingPhase 2
L19IL2 and L19TNF for advanced basal cell carcinoma
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
Tampa, FloridaAges 18 years+ - NCT06325709RecruitingPhase 1/Phase 2
Gene editing trial for X-linked chronic granulomatous disease
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
Bethesda, MarylandAges 18–75 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Daphne, AlabamaAges 18 years+ - NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT07219212RecruitingPhase 1
New drug with chemo and radiation for advanced head and neck cancer
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
Birmingham, AlabamaAges 18–74 - NCT07172256RecruitingPhase 2
CUE-101 plus pembrolizumab for HPV+ throat cancer
This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Birmingham, AlabamaAges 18 years+ - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Birmingham, AlabamaAges Any age - NCT06926894RecruitingPhase 1
A cell therapy for viral infections in children and young adults
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
New York, New YorkAges 3 months–26 years - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT06785818Recruiting
Long-term follow-up of Kymriah patients in South Korea
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
Bundang Gu, Gyeonggi-doAges birth–100 years - NCT06947460RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant lupus, sclerosis, and Sjögren's lung disease
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
Beijing, China,BeijingAges 10–65 - NCT07623356RecruitingPhase 1/Phase 2
Study of AK138D1 alone or with ivonescimab for advanced lung cancer
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03704766Recruiting
Testing fluid markers to detect pediatric joint infections
This study checks special lab markers in joint fluid to tell septic (infected) arthritis apart from other inflammatory causes in children. It may help clinicians detect infection more accurately and quickly so kids can get the right treatment.
Atlanta, GeorgiaAges Up to 17 years - NCT02447874RecruitingPhase 1/Phase 2
Arginine treatment for children’s sickle cell pain
This early-phase study tests whether arginine can help control pain in children with sickle cell disease. You may be considered if your child is having a sickle cell pain episode that needs stronger pain medicine given through an IV.
Atlanta, GeorgiaAges 7–21
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,686 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.